Top Questions Ahead for Cancer Immunotherapy
A decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put… Read More »Top Questions Ahead for Cancer Immunotherapy
A decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put… Read More »Top Questions Ahead for Cancer Immunotherapy
*The information in this blog post is based on the webinar, “Understanding Cancer-related Cognitive Impairment,” hosted by the Kimmel Cancer Center's Breast Cancer Program. Q: What… Read More »8 Tips for Improving Cognition During and After Cancer Treatment
More than 20 years ago, when Johns Hopkins scientists Bert Vogelstein, Ken Kinzler and their colleagues linked certain cancers to mutations in genes that repair DNA,… Read More »Research from Bloomberg-Kimmel Institute Among Best of #ASCO2017
On a block of vacant row homes near the Johns Hopkins Medicine campus in East Baltimore, the Ulman Cancer Fund is building an 8,000 square-foot… Read More »Ulman Fund breaks ground on residence for young adults with cancer
What cancer screenings do I need and when? If this answer isn't clear to you, listen to Kimmel Cancer Center director William Nelson moderate a… Read More »Kimmel Cancer Center Director Moderates AACR Webinar on Cancer Screening Guidelines
The Johns Hopkins Greenberg Bladder Cancer Institute recently announced a joint effort with the Bladder Cancer Advocacy Network (BCAN) to fund up to two awards totaling… Read More »What’s next for bladder cancer research?
Nearly 19,000 de-identified genomic records from cancer patients treated by an international group of hospitals, including the Johns Hopkins Kimmel Cancer Center, have been collected… Read More »Scientists let GENIE data “out of the bottle”
Immunotherapy has become one of the hottest areas of cancer research, and the number of cancers successfully treated by immunotherapy is growing. Nearing the end… Read More »5 Things We Learned About Immunotherapy This Year
A ceremony was held yesterday at the White House to sign the 21st Century Cures Act, which authorizes $4.8 billion in National Institutes of Health funding… Read More »President Obama Signs 21st Century Cures Act
In a head-to-head comparison between the immunotherapy drug pembrolizumab and standard chemotherapy as a first-line therapy for advanced nonsmall cell lung cancer, patients taking pembrolizumab had… Read More »Immunotherapy drug staves off lung cancer better than chemo in some newly treated patients